The unmet medical need in oncology is changing. While immunotherapies have transformed the treatment of some cancers, they are only available to, and effective in, a small subset of patients. Bringing the power of immunotherapies to more patients is now the defining challenge of oncology R&D. Recognizing that, Alkermes is using R&D capabilities honed over 30 years of work on complex, hard-to-treat diseases to investigate a potential next breakthrough in cancer therapy.